TY  - GEN
AU  - Siegel,David S
AU  - Martin,Thomas
AU  - Wang,Michael
AU  - Vij,Ravi
AU  - Jakubowiak,Andrzej J
AU  - Lonial,Sagar
AU  - Trudel,Suzanne
AU  - Kukreti,Vishal
AU  - Bahlis,Nizar
AU  - Alsina,Melissa
AU  - Chanan-Khan,Asher
AU  - Buadi,Francis
AU  - Reu,Frederic J
AU  - Somlo,George
AU  - Zonder,Jeffrey
AU  - Song,Kevin
AU  - Stewart,A Keith
AU  - Stadtmauer,Edward
AU  - Kunkel,Lori
AU  - Wear,Sandra
AU  - Wong,Alvin F
AU  - Orlowski,Robert Z
AU  - Jagannath,Sundar
TI  - A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
SN  - 1528-0020
PY  - 2012///1218
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Neoplasm Recurrence, Local
KW  - Neoplasm Staging
KW  - Oligopeptides
KW  - therapeutic use
KW  - Pilot Projects
KW  - Prognosis
KW  - Salvage Therapy
KW  - Survival Rate
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1182/blood-2012-05-425934
ER  -